Turnidge J
Department of Microbiology and Infectious Diseases, Monash Medical Centre, Victoria, Australia.
Drugs. 1995;49 Suppl 2:43-7. doi: 10.2165/00003495-199500492-00008.
Both nalidixic acid and fluoroquinolones are used widely in the Eastern hemisphere for a variety of infectious diseases. A surveillance programme for antibiotic resistance in common pathogens has been conducted in the Western Pacific Region of the World Health Organization since 1989. Data on resistance to fluoroquinolones for the years 1992 and 1993 from the 16 participating countries in the Western Pacific, plus published data from Thailand, were collated for common and important pathogens in this region. Overall, fluoroquinolone resistance levels were highest in developing countries and lowest in developed countries, with transitional countries undergoing rapid economic improvement showing intermediate levels of resistance. There was also a trend towards increasing levels of fluoroquinolone resistance between 1992 and 1993. In developed countries, levels of resistance to fluoroquinolones exceeded 10% for only Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter and Providencia species. Resistance levels of 25% or more in Escherichia coli were noted in 3 countries in 1993. In contrast, resistant strains of Salmonella typhi and S. paratyphi A were rare or nonexistent in any country, and only low levels of resistance were detected in Shigella species. Fluoroquinolone resistance appears to be emerging slowly in developed countries and more rapidly in transitional and developing countries. Strenuous efforts will be required in some countries in order to prevent the early obsolescence of these valuable agents.
萘啶酸和氟喹诺酮类药物在东半球被广泛用于治疗多种传染病。自1989年以来,世界卫生组织西太平洋区域开展了一项针对常见病原体抗生素耐药性的监测计划。整理了1992年和1993年西太平洋16个参与国对氟喹诺酮类药物耐药性的数据,以及泰国已发表的数据,涉及该区域常见且重要的病原体。总体而言,氟喹诺酮类药物耐药水平在发展中国家最高,在发达国家最低,经济快速发展的转型国家耐药水平处于中间。1992年至1993年期间,氟喹诺酮类药物耐药水平也呈上升趋势。在发达国家,仅铜绿假单胞菌、金黄色葡萄球菌、不动杆菌属和普罗威登斯菌属对氟喹诺酮类药物的耐药水平超过10%。1993年,有3个国家的大肠杆菌耐药水平达到或超过25%。相比之下,伤寒沙门菌和甲型副伤寒沙门菌的耐药菌株在任何国家都很罕见或不存在,志贺菌属的耐药水平也很低。氟喹诺酮类药物耐药性在发达国家似乎正在缓慢出现,而在转型国家和发展中国家出现得更快。一些国家需要付出巨大努力,以防止这些宝贵药物过早过时。